- COSMO ANNOUNCES FULL-YEAR RESULTS 2021; CONFIRMS BEATING GUIDANCE
- First U.S. trial using GI Genius(TM) intelligent endoscopy module shows 50% reduction in missed colorectal polyps with Artificial Intelligence (AI) technology versus standard colonoscopy
- Invitation to Cosmo's full-year 2021 results and 2022 outlook webcast presentation on 23 March 2022
Key statistics
On Friday, Cosmo Pharmaceuticals NV (COPN:SWX) closed at 53.50, 11.81% above the 52 week low of 47.85 set on May 10, 2022.
52-week range
Markit short selling activity
Open | 52.80 |
---|---|
High | 54.20 |
Low | 52.50 |
Bid | 50.30 |
Offer | 56.60 |
Previous close | 52.80 |
Average volume | 18.65k |
---|---|
Shares outstanding | 17.54m |
Free float | 10.09m |
P/E (TTM) | 51.27 |
Market cap | 938.19m CHF |
EPS (TTM) | 1.04 CHF |
Data delayed at least 15 minutes, as of May 20 2022 16:30 BST.
More ▼